



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editors**  
Andreina Fernandes (Venezuela)  
Aarthi S. Jayraj (United Kingdom)

**Managing Editor**  
Emily Hammond (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jmeditorial.com](mailto:ijgc@jmeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](http://support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/productservices/rights-and-licensing/](http://bmj.com/company/productservices/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2023 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

*The International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead Article

- 1675** Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?

*H Mahdi, I Ray-Coquard, D Lorusso, M R Mirza, B J Monk, B Slomovitz*

## Editorial

- 1682** Combination of hormonal-based therapy in endometrial cancer: ready for prime time

*M C Santia, J C Vilches, P T Ramirez*

## Cervical Cancer

- 1684** MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial?

*R Nitecki, P T Ramirez, P Dunder, K Nemejcova, R Ribeiro, M T Vieira Gomes, R L Schmidt, L Bedoya, D O Isla, R Pareja, G J Rendón Pereira, A Lopez, D Kushner, D Cibula*

- 1690** PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study

*M Frumovitz, A C Morani, A Aziz, A Jhingran, P Ramalingam, N R Gonzales, G Salvo, J Sun, P Bhosale*

- 1695** Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer

*N Michaan, A Wenkert, E Even-Sapir, K Kerzhner, T Rabin, T Safra, S Peleg-Hasson, Y Baruch, Y Raz, D Grisaru, I Laskov*

## Uterine Cancer

- 1702** Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer

*F Siegenthaler, E Epstein, C A Büchi, A Gmür, F A C M Saner, T T Rau, J W Carlson, M D Mueller, S Imboden*

- 1708** Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework

*V Bruno, M Betti, L D'Ambrosio, A Massacci, B Chiofalo, A Pietropolli, G Piaggio, G Ciliberto, P Nisticò, M Pallocca, A Buda, E Vizza*

- 1715** Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England

*S Goulden, K Heffernan, F Sen Nikitas, U Shukla, C Knott, M Hunger, A Pahwa, R Schade*

- 1724** Gestational trophoblastic neoplasia: does centralization of care impact clinical management?

*C Mitric, K Yang, G Bhat, S Lheureux, S Laframboise, X Li, G Bouchard-Fortier*

## Ovarian Cancer

- 1733** Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

*T J Herzog, S A Wahab, M R Mirza, B Pothuri, I Vergote, W S Graybill, I A Malinowska, W York, J A Hurteau, D Gupta, A González-Martin\*, B J Monk\**

- 1743** Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy

*O-J Kang, S-W Lee, J-H Kim, J-Y Park, D-S Suh, D-Y Kim, J-H Kim, Y-M Kim, Y-T Kim*

- 1750** Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study

*A Bergamini, R Ramaswami, F Froeling, P Papanastasiopoulos, D Short, X Aguiar, P M Savage, N Sarwar, B Kaur, S Saso, C Fotopoulou, A Sharma, G J S Rustin, M Seckl*

- 1757** The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer

*P J Fagan, N Gomes, O M Heath,  
D Chandrasekaran, S-E Yao, L Satchwell,  
A George, S Banerjee, A Sohaib, D P Barton,  
M Nobbenhuis, T Ind, J Butler*

- 1764** Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study

*W Shen, C Jing, W Tian, W Zhang, Y Ren, B Shan,  
H Wang*

- 1771** Short- and long-term morbidity of total parietal peritonectomy for advanced ovarian cancer

*S Odajima, H Tanabe, Y Koike, J Onishi,  
T Ichikawa, K Yokosu, S Takaneke, A Okamoto*

## Surgery

- 1778** Characterization of pre-operative anemia in patients undergoing surgery by a gynecologic oncologist and association with post-operative complications

*O W Foley, B Vega, D Roque, E Hinchcliff,  
J Marcus, E J Tanner, E L Barber*

- 1786** Cost impact analysis of enhanced recovery after minimally invasive gynecologic oncology surgery



*C Mitric, S D Kosa, S R Kim, G Nelson,  
S Laframboise, G Bouchard-Fortier*

- 1794** Thoracic epidural analgesia as part of an enhanced recovery program in gynecologic oncology: a prospective cohort study

*A Pandrakis, D Haidopoulos, T Lappas,  
E Stamatakis, D Valsamidis, M D Oikonomou,  
D Loutradis, A Rodolakis, S P Bisch, G Nelson,  
N Thomakos*

## Review

- 1800** Impact of gynecological cancers on health-related quality of life: historical context, measurement instruments, and current knowledge



*B Gil-Ibanez, J Davies-Oliveira, G Lopez,  
B Díaz-Feijoo, A Tejerizo-García, J Sehoul*

## Clinical trial

- 1807** Personalized Treatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial

*M Loukovaara, R Bützow, S Staff, M Mäenpää,  
M Faltinová, H Lassus, O Vejjalainen, M Grö,  
L Vaalavirta, E Kuikka, M Haataja, E Urpilainen,  
M Simojoki, M Anttila, A Auranen*

## Tumor board

- 1812** Serous endometrial cancer confined to a polyp with malignant pleural effusion

*J Mauro, F Filippello, E Tripodi, G Di Guardia,  
A Buda*

## Corners of the world

- 1819** The Australian Society of Gynaecological Oncology Western Pacific Liaison group

*E R Allanson, M Burling, B Simcock, J Nicklin,  
P H Sykes*

## Video articles

- 1821** Right diaphragmatic peritonectomy in extensive involvement of the coronary area: no touch principle

*G Khatib, M Misirlioglu, M Varli,  
U Kucukgoz Gulec, A B Güzel, M A Vardar*

- 1823** Inguinofemoral lymphadenectomy technique in 10 steps

*A Luzarraga Aznar, A Pérez-Benavente,  
S Cabrera, V Bebia, A Gil-Moreno,  
M A Angeles*

- 1825** Autologous heterotopic fresh ovarian graft: technique description

*M A Bertolazzi, R P Fernandes, M L N D Genta,  
E C Baracat, J P Carvalho*

## Pathology archives

- 1827** Cotyledonoid dissecting leiomyoma of the uterus: a gross and radiologic malignancy mimicker

*R F Abreu, G Bovolim, G Baiocchi, L De Brot*

- 1830** Sebaceous differentiation can occur in vulvar adenoid cystic carcinoma

*FNU Mahjabin, Z Ordulu, E Martinez-Duarte, S M Falzarano*

---

## Images

- 1833** Ischemic bowel associated with newly diagnosed patent foramen ovale

*H Hong, D Glassman, S N Westin*

---

## Commentary

- 1835** Breaking the silence: the taboo surrounding HPV vaccination in Morocco

*F Kouhen, A El Ghanmi*

---

## Letter

- 1836** Correspondence on 'Thoracic epidural analgesia as part of an enhanced recovery program in gynecologic oncology: a prospective cohort study' by Pandrakis et al

*F-S Xue, N He, Y Cheng*